Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma

SMARCA4 (switch/sucrose non‐fermentable‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4)‐deficient thoracic tumours have shown poor prognosis in clinical settings. Although the optimal treatment for SMARCA4‐deficient thoracic tumours remains unclear, existin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiba, Yosuke, Kawanami, Toshinori, Yamasaki, Kei, Uchimura, Keigo, Matsuyama, Atsuji, Yatera, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506996/
https://www.ncbi.nlm.nih.gov/pubmed/32995013
http://dx.doi.org/10.1002/rcr2.667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506996/
https://www.ncbi.nlm.nih.gov/pubmed/32995013
http://dx.doi.org/10.1002/rcr2.667

Ejemplares similares